Allergic Conjunctivitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for allergic conjunctivitis. 68 active patents protecting 6 drugs from 5+ originators. First major cliff: 2027. Daily refresh.

6
Approved drugs
68
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Allergic Conjunctivitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 32 patents Generic (originally Merck/Upjohn) 29 patents Bayer 3 patents AbbVie 2 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating allergic conjunctivitis. Each bar = one year. Y-axis scaled to peak year (34 patents).

5
27
2
28
3
30
7
32
34
33
7
34
3
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotemax
LOTEPREDNOL ETABONATE
 Bausch Health 32 42 — 2033-05-03
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28
Lastacaft
ALCAFTADINE
 AbbVie 2 80 — 2027-03-19
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10617695 Lastacaft method of use 80 2027-03-19
8664215 Lastacaft method of use 80 2027-12-23
8869794 Tobi method of use 75 2028-09-12
12133914 Cortef method of use 75 2043-02-23
11904046 Cortef method of use 75 2043-02-23
10207066 Tobi method of use 68 2030-11-04
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
9393213 Lotemax formulation 25 2033-05-03
10646437 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10646436 Lotemax formulation 25 2033-05-03
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14

Related